Perrigo Launch Investments Hold Income Back, As Firm Girds For 2013
This article was originally published in The Tan Sheet
Perrigo’s consumer business’ 2012 full-year operating income, after GAAP adjustments, increased only 0.8% to $304.96 million, despite the division’s 8% revenue growth to $131 million for the fiscal year. The firm plans to launch more than 60 new products in fiscal 2013.
You may also be interested in...
FDA denied Perrigo’s petition that had sought to block Dr. Reddy’s ANDA for generic Prevacid 24HR because it used bioequivalence data for the proton pump inhibitor’s Rx version. Competition between the firms is intensifying as Dr. Reddy’s expands its U.S. OTC presence.
The latest delay in Johnson & Johnson’s remediation of its McNeil OTC manufacturing pushes back FDA’s review of the Fort Washington, Pa., facility to “late 2013.” The firm’s Q1 results saw the worldwide consumer business fall 2.4% to $3.60 billion, including negative currency exchange effects.
After shuttering its Lincoln, Neb., OTC facility, the firm recalls some lots of Bufferin, Excedrin, Gas-X and NoDoz. FDA found a “pattern of problems” when inspecting the plant in 2011, and Novartis’ actions suggest it seeks to avoid the same scrutiny that Johnson & Johnson’s OTC recalls elicited.